Key facts
- This page summarizes Brett R. Hagen's Form 4 filing for InMed Pharmaceuticals Inc. (MTRI).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Nov 2026, 16:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
This option represents the right to purchase 171,000 shares of the Issuer's common stock and will vest as to 25% on November 9, 2027 and in equal monthly installments thereafter through November 9, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
SEC remarks
Senior Vice President, Finance and Chief Accounting Officer